EligibleTrials

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Recruiting · NCT06830629 · Interventional (participants receive a specific treatment) · Lead sponsor: Maze Therapeutics

View the official record on ClinicalTrials.gov →
Chronic kidney disease

Interventions studied

MZE829

What this trial is about

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Who can take part

Age range
18 Years to 68 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 24 US states.

Showing 60 of 79 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.